This week we say farewell to Zurich and head North, through Germany where we arrive at our next destination, the capital city of Denmark, Copenhagen. This amazing city is famous for the Little Mermaid Statue, the autonomous neighborhood of Christiania and Tivoli Gardens Amusement Park. It is also home to our biotech of the week: Zealand Pharma.


2334669_logo_large

City: Copenhagen

Founded: 1998

Financial Data: €3.52B Market Cap (on 11/2015)

Employees: 112 (as of 12/2015)

CEO:

President and CEO, Britt Meelby Jensen

President and CEO, Britt Meelby Jensen

Mission: Zealand Pharma is a biotech company that has the primary mission to turn peptides into medicines. They focus on diseases which they believe current treatments fail the patient’s medical needs and could benefit from peptide-based medicines. The company focuses on 3 therapeutic areas: metabolic, gastrointestinal and cardiovascular diseases. At present, Zealand has one marketed product through a development partnership with Sanofi, Lixisenatide, a treatment of type II diabetes, along with several phase III products and multiple phase I/II in it’s partnered pipeline and it’s own proprietary pipeline. Zealand has also formed development partnerships with other pharma companies including Eli Lilly and Boehringer Ingelheim.

Comments: We visited Zealand for our Denmark Tour and we were pretty impressed by the track record of the company. It signed massive deals with great partners and has succeeded in building up a sustainable company (one partnered product on the market). It’s definitely a success-story made in Denmark and a company close to watch in the coming years.


We visited Zealand Pharma on our Labiotech Tour of Denmark…

ADVERTISEMENT
Previous post

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Next post

Digital CRISPR Cloud Services: An Appealing Product to Big Bioinformatics Investors like Illumina